Drug recall · March 13, 2019
BuPROPion Hydrochloride Extended-Release Tablets recall
Why: Failed Dissolution Specifications; 9-monthstability timepoint
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150 mg, a) 30 count (NDC 59746- 758-30) & b) 90 count (NDC 59746-758-90) bottles, Rx only, Manufactured b Jubilant Generis Ltd, Roorkee, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD
- Lots / codes
a) BR117002C, exp. date 11/2019; b) BR117003B and BR117004B, exp. date 11/2019
- Quantity
- a) 3,072 bottles; b) 2,688 bottles
- Company
- Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD
- Distribution
- Product was distributed to one customer who may have further distributed the product.
- Initiated
- February 28, 2019 · Voluntary: Firm initiated
- Classified
- March 6, 2019
- Reported
- March 13, 2019
- Ended
- March 5, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bupropion
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.